Salivary and lacrimal gland involvement in a patient who had undergone a thyroidectomy and was treated with radioiodine for thyroid cancer

Markitziu, A; Lustmann, J.; Uzieli, Beatrice; Krausz, Yodfat; Chisin, Roland

doi:10.1016/0030-4220(93)90144-s

Cited by 44 publications

(19 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Moreover, in the ducts of salivary glands, an active I Ϫ transport system provides for a higher concentration of I Ϫ in saliva, compared with plasma (1). Consequently, radioiodine ( 131 I) therapy may produce significant damage to salivary glands, resulting in salivary dysfunction in a significant number of patients, most likely as a result of radioiodine uptake and concentration in the striated ducts of the salivary glands (9). Similarly, I…”

Section: Discussionmentioning

confidence: 99%

“…Additionally, several normal and abnormal tissues, such as nonlactating mammary gland, lacrimal gland, nasopharynx, thymus, skin, placenta, inflammatory lung tissue, and lung carcinoma (7)(8)(9)(10)(11)(12)(13), have been reported to take up radioiodine. The iodide transport system in these extrathyroidal tissues reveals several functional similarities to its thyroid counterpart, such as inhibition of iodide transport by thiocyanate and perchlorate (1).…”

mentioning

confidence: 99%

See 1 more Smart Citation

Analysis of Human Sodium Iodide Symporter Gene Expression in Extrathyroidal Tissues and Cloning of Its Complementary Deoxyribonucleic Acids from Salivary Gland, Mammary Gland, and Gastric Mucosa

Spitzweg¹,

Joba²,

Eisenmenger³

et al. 1998

The Journal of Clinical Endocrinology & Metabolism

297

102

View full text Add to dashboard Cite

The ability to concentrate iodide is a fundamental property of normally functioning thyroid tissue and represents the first step in the production of thyroid hormones. Iodide uptake has been demonstrated in various extrathyroidal tissues, including salivary gland, gastric mucosa, and lactating mammary gland. Recently, cloning and molecular characterization of the human sodium iodide symporter (hNIS) have been reported; however, the patterns of hNIS gene expression in human tissues have remained unidentified. To examine the profiles of human hNIS gene expression in various normal human tissues, we performed high-stringency Northern blot analysis using a 32 P-labeled hNIS-specific complementary DNA (cDNA) probe (nucleotides 1184 -1667). To detect rare hNIS transcripts in small tissue samples, RT-PCR was performed with a pair of hNIS-specific oligonucleotide primers designed to amplify a portion (nucleotides 1184 -1667) of the hNIS gene. hNIS-specific transcripts were confirmed by Southern hybridization using a digoxigenin-labeled internal hNISspecific oligonucleotide probe (nucleotides 1460 -1477). To monitor cDNA integrity and quantity, and to rule out DNA contamination and illegitimate transcription, all samples were coamplified with two pairs of intron-spanning primers designed to amplify fragments of the human ␤-actin and thyroglobulin genes, respectively. Using Northern blot analysis, hNIS transcripts of approximately 4 kb were detected in thyroid gland and parotid gland but not in a broad range of endocrine and nonendocrine tissues. RT-PCR and Southern hybridization revealed hNIS gene expression in thyroid gland, salivary gland, parotid gland, submandibular gland, pituitary gland, pancreas, testis, mammary gland, gastric mucosa, prostate and ovary, adrenal gland, heart, thymus, and lung. By contrast, hNIS transcripts were not detected in normal orbital fibroblasts, colon, and nasopharyngeal mucosa. To further analyze hNIS gene sequences in parotid gland, mammary gland, and gastric mucosa, the EXPAND High Fidelity PCR System and three sets of overlapping NIS oligonucleotide primers were used for amplification and cloning. The resulting PCR products were subcloned into pBluescript-SK II (Ϫ) vector, and at least two independent cDNA clones derived from each tissue were subjected to automated sequencing. The nucleotide sequences of hNIS cDNA derived from parotid gland, mammary gland, and gastric mucosa revealed full identity with the recently published human thyroidderived NIS cDNA sequence. In conclusion, our results demonstrate markedly variable levels of hNIS gene expression in several extrathyroidal tissues. Although the physiological role of hNIS in these tissues awaits further study, our results suggest that the capacity to actively transport iodine may be a feature common to several secretory and endocrine tissues. The diminished capacity to transport and concentrate iodide in extrathyroidal tissues (such as parotid gland, mammary gland, and gastric mucosa), compared with thyroid gland, does not s...

show abstract

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

Analysis of Human Sodium Iodide Symporter Gene Expression in Extrathyroidal Tissues and Cloning of Its Complementary Deoxyribonucleic Acids from Salivary Gland, Mammary Gland, and Gastric Mucosa

Spitzweg¹,

Joba²,

Eisenmenger³

et al. 1998

The Journal of Clinical Endocrinology & Metabolism

297

102

View full text Add to dashboard Cite

show abstract

“…As complicações sistêmicas da RIT geralmente são leves e fugazes, sendo bem estabelecido o acometimento de glândulas salivares com subsequente xerostomia (4,5) . As complicações oculares são pouco relatadas (6) , sendo descritas conjuntivite crônica e recorrente, ceratoconjuntivite seca e xeroftalmia (7) . A disfunção de glândula lacrimal é descrita em estudos recentes, notadamente após alta dose cumulativa do fármaco (8,9) .…”

Section: Introductionunclassified

Obstrução de vias lacrimais associada ao tratamento radioiodoterápico de carcinoma de tireoide

Fonseca

Lunardelli²,

Matayoshi³

2012

Arq. Bras. Oftalmol.

View full text Add to dashboard Cite

“…Actualmente en algunos centros, incluido el nuestro, se han ajustado las dosis y la indicación de RAI a cada caso en particular, dependiendo de los factores que en el paciente condicionan mayor riesgo de recurrencia y falla del tratamiento en general [3][4][5] . La incidencia de efectos colaterales de la aplicación de RAI utilizado como ablación ha sido publicada en variados estudios, con síntomas de patología salival alejada hasta en un 39% de los pacientes [6][7][8] . Los síntomas derivados del efecto del RAI sobre el tejido glandular salival y lagrimal corresponden a xerostomia, dolor y aumento de volumen, sequedad ocular y alteraciones del gusto [6][7][8][9] .…”

unclassified

“…La incidencia de efectos colaterales de la aplicación de RAI utilizado como ablación ha sido publicada en variados estudios, con síntomas de patología salival alejada hasta en un 39% de los pacientes [6][7][8] . Los síntomas derivados del efecto del RAI sobre el tejido glandular salival y lagrimal corresponden a xerostomia, dolor y aumento de volumen, sequedad ocular y alteraciones del gusto [6][7][8][9] . La acción del radioyodo sobre el tejido salival ha sido explicada en estudios previos 10 y tendría efecto clínico variable de acuerdo a la dosis utilizada y acumulada.…”

unclassified

Incidencia De Patología Salival Sintomática Alejada en Pacientes Tratados Con Yodo Radioactivo Por Cáncer Diferenciado De Tiroides

et al. 2015

Rev Chil Cir

View full text Add to dashboard Cite

incidence of sympthomatic salivary disease in patients with differentiated thyroid cancer treated with radioactive iodine Background: The radioactive iodine therapy for differentiated thyroid cancer can produce severe and frequent salivary symptoms, during the treatment or later. aim: To analyze the incidence, severity and charactheristics of the salivary signs and symptoms in these patients. Patients and Method: Retrospective and descriptive analisis of 106 patients with confirmed diagnosis of differentiated thyroid cancer, treated with surgery and radioactive iodine, that completed a telephonic survey for the evaluation of salivary symptoms. results: 26 (24.52%) patients presented with salivary symptoms or signs after the radioactive iodine therapy (mean 5 months). The average doses of I 131 was 128,5 mCi. Xerostomy, pain, xeroftalmy, inflammation, sialoadenitis and dysgeusia, were the most frequent clinical symptoms. conclusions: After radioactive iodine therapy the salivary symptoms and signs incidence is high. We conclude that the indication for this treatment must be selective, but in accordance with the oncological risk of each patient.

show abstract

Salivary and lacrimal gland involvement in a patient who had undergone a thyroidectomy and was treated with radioiodine for thyroid cancer

Cited by 44 publications

References 6 publications

Analysis of Human Sodium Iodide Symporter Gene Expression in Extrathyroidal Tissues and Cloning of Its Complementary Deoxyribonucleic Acids from Salivary Gland, Mammary Gland, and Gastric Mucosa

Analysis of Human Sodium Iodide Symporter Gene Expression in Extrathyroidal Tissues and Cloning of Its Complementary Deoxyribonucleic Acids from Salivary Gland, Mammary Gland, and Gastric Mucosa

Obstrução de vias lacrimais associada ao tratamento radioiodoterápico de carcinoma de tireoide

Incidencia De Patología Salival Sintomática Alejada en Pacientes Tratados Con Yodo Radioactivo Por Cáncer Diferenciado De Tiroides

Contact Info

Product

Resources

About